No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 27 of the 40 quarters in the window, leaving 13 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 13.7x · 10Y median 6.0x · 65th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:55:47.428Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T11:55:47.428Z. Latest historical point 2026-05-12. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T11:55:47.428Z. Latest historical point 2026-05-12.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T11:55:47.428Z. Latest historical point 2026-05-12. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Atara Biotherapeutics, Inc. (ATRA) stock was $9.40 as of Oct 5, 2026, 4:00 PM EDT, down 0.84% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -34.6% · 3-year avg -35.5%/yr · 5-year avg -53.6%/yr
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies.
Biotechnology · Thousand Oaks, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.13
Revenue Est.
$800000.00
Last Quarter Results
EPS
$-0.32
vs Estimate
$-0.32
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ATRA | $84.70M | $9.40 | -0.84% | -34.63% | -53.60% | -32.27% | N/A |
| 2ACRV | $84.75M | $1.98 | -0.50% | +3.65% | N/A | N/A | vs ATRA |
| 3CGTX | $83.96M | $0.94 | +1.41% | -39.33% | N/A | N/A | vs ATRA |
| 4CNXU | $83.49M | $3.12 | +0.65% | N/A | N/A | N/A | vs ATRA |
| 5CCLD | $86.69M | $2.04 | +0.99% | -39.68% | -23.18% | +8.53% | vs ATRA |
| 6CRDF | $87.86M | $1.14 | +1.79% | -47.78% | -30.36% | -43.20% | vs ATRA |
forward FY estimate
N/A
$630000.00
vs Estimate
$550000.00
Consensus Rating
Based on 3 analysts
Average Price Target
$13.67
+45.4% upside
Low
$10.00
Current
$9.40
High
$18.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.20 | $-0.13 | $-0.07 | 2 |
| Quarter ending Dec 2026 | $-0.15 | $-0.09 | $-0.03 | 2 |
| Quarter ending Mar 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Quarter ending Jun 2027 | $1.00 | $1.00 | $1.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.98 | $-0.69 | $0.63 | 2 |
| FY 2027 | $0.14 | $0.94 | $1.75 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $800000.00 | $800000.00 | $800000.00 | 3 |
| Quarter ending Dec 2026 | $1.35M | $1.35M | $1.35M | 3 |
| Quarter ending Mar 2027 | $700000.00 | $700000.00 | $700000.00 | 1 |
| Quarter ending Jun 2027 | $31.70M | $31.70M | $31.70M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.25M | $2.85M | $3.78M | 2 |
| FY 2027 | $36.12M | $45.65M | $60.55M | 2 |
